 |
0 Diseases |  |
13 Trials |
|
13 Trials |  |
453 News |  |
| «1234567» |
- Baize'an (tislelizumab) / BeiGene, Novartis, sitravatinib (MGCD516) / Mirati
Safety and efficacy of Sitravatinib + Tislelizumab in patients with PD-L1+, locally advanced/metastatic, nonsquamous NSCLC (Great Hall 3&4) - Oct 20, 2022 - Abstract #COSA2022COSA_182;
P1b
Acknowledgments: This study was sponsored by BeiGene, Ltd. Medical writing support for the development of this abstract, under the direction of the authors, was provided by Tamsin Grewal, MSc, and Louise Oakes, PhD, of Ashfield MedComms, an Inizio company, and was funded by BeiGene, Ltd.
- || sitravatinib (MGCD516) / BeiGene, Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Enrollment closed, Combination therapy, Metastases: Study of Sitravatinib, Nivolumab and Ipilimumab in Advanced or Metastatic Clear-Cell Renal Cell Carcinoma or Other Solid Malignancies (clinicaltrials.gov) - Oct 12, 2022
P1, N=92, Active, not recruiting, Sponsor: Mirati Therapeutics Inc.
Medical writing support for the development of this abstract, under the direction of the authors, was provided by Tamsin Grewal, MSc, and Louise Oakes, PhD, of Ashfield MedComms, an Inizio company, and was funded by BeiGene, Ltd. Enrolling by invitation --> Active, not recruiting
- || sitravatinib (MGCD516) / BeiGene, Opdivo (nivolumab) / BMS
Enrollment closed, Trial completion date, Trial primary completion date, Metastases: PK Study to Assess Drug-drug Interaction and QTc Between Sitravatinib and a Cocktail of Substrates (clinicaltrials.gov) - Oct 10, 2022
P1, N=48, Active, not recruiting, Sponsor: Mirati Therapeutics Inc.
Enrolling by invitation --> Active, not recruiting Recruiting --> Active, not recruiting | Trial completion date: Dec 2022 --> Dec 2023 | Trial primary completion date: Jun 2022 --> Jun 2023
- Baizean (tislelizumab) / BeiGene, Novartis, sitravatinib (MGCD516) / Mirati
A phase II study of tislelizumab (TIS) plus sitravatinib as adjuvant therapy in patients with hepatocellular carcinoma (HCC) at high risk of recurrence after surgical resection (Exhibition / Poster Area) - Oct 9, 2022 - Abstract #ESMOAsia2022ESMO_Asia_604;
P2
Primary endpoint is 2-year recurrence-free survival (RFS) rate. Secondary endpoints include RFS, time to recurrence, overall survival (OS), 1-year RFS rate, 1-year and 2-year OS rate, and safety.
- |||||||||| Tevimbra (tislelizumab-jsgr) / BeiGene, sitravatinib (MGCD516) / BeiGene
New P3 trial: Efficacy and Safety of Sitravatinib Plus Tislelizumab or Placebo Plus Tislelizumab Versus Placebo as Adjuvant Treatment in Participants With Hepatocellular Carcinoma (clinicaltrials.gov) - Oct 3, 2022
P3, N=624, Not yet recruiting, Sponsor: BeiGene
- | sitravatinib (MGCD516) / BeiGene, Opdivo (nivolumab) / BMS
Trial completion, Trial completion date, Trial primary completion date, Metastases: Sitravatinib and Nivolumab in Treating Patients With Advanced or Metastatic Kidney Cancer (clinicaltrials.gov) - Oct 3, 2022
P1/2, N=42, Completed, Sponsor: M.D. Anderson Cancer Center
Secondary endpoints include RFS, time to recurrence, overall survival (OS), 1-year RFS rate, 1-year and 2-year OS rate, and safety. Active, not recruiting --> Completed | Trial completion date: Apr 2024 --> Sep 2022 | Trial primary completion date: Apr 2023 --> Sep 2022
- || Tevimbra (tislelizumab-jsgr) / BeiGene, sitravatinib (MGCD516) / BeiGene
Enrollment open, Combination therapy, Metastases: SITISVEAL: Sitravatinib and Tislelizumab in Patients With Metastatic Uveal Melanoma With Liver Metastases. (clinicaltrials.gov) - Sep 29, 2022
P2, N=34, Recruiting, Sponsor: Grupo Espa
Active, not recruiting --> Completed | Trial completion date: Apr 2024 --> Sep 2022 | Trial primary completion date: Apr 2023 --> Sep 2022 Not yet recruiting --> Recruiting
- || Tevimbra (tislelizumab-jsgr) / BeiGene, sitravatinib (MGCD516) / BeiGene
New P2 trial, Combination therapy, Metastases: SITISVEAL: Sitravatinib and Tislelizumab in Patients With Metastatic Uveal Melanoma With Liver Metastases. (clinicaltrials.gov) - Sep 15, 2022
P2, N=34, Not yet recruiting, Sponsor: Grupo Espa
- || sitravatinib (MGCD516) / BeiGene, Keytruda (pembrolizumab) / Merck (MSD)
Enrollment open, Mismatch repair: Pembrolizumab With Sitravatinib in Recurrent Endometrial Cancer and Other Solid Tumors With Deficient Mismatch Repair System (clinicaltrials.gov) - Sep 14, 2022
P2, N=30, Recruiting, Sponsor: Haider Mahdi
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- || sitravatinib (MGCD516) / BeiGene
Enrollment closed: PK Study to Assess Drug-drug Interaction Between Sitravatinib and a P-gp Inducer and an Inhibitor. (clinicaltrials.gov) - Aug 26, 2022
P1, N=36, Active, not recruiting, Sponsor: Mirati Therapeutics Inc.
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- || sitravatinib (MGCD516) / Mirati
Enrollment closed: A Study to Evaluate the Effect of Mild, Moderate, and Severe Hepatic Impairment on Pharmacokinetics of Sitravatinib (clinicaltrials.gov) - Aug 26, 2022
P1, N=30, Active, not recruiting, Sponsor: Mirati Therapeutics Inc.
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- || sitravatinib (MGCD516) / BeiGene
Trial completion: A Study to Explore the Effect of Acid-reducing Agents (clinicaltrials.gov) - Aug 26, 2022
P1, N=15, Completed, Sponsor: Mirati Therapeutics Inc.
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- || sitravatinib (MGCD516) / Mirati
P1 data, Clinical Trial,Phase I, Journal: First-in-human phase 1/1b study to evaluate sitravatinib in patients with advanced solid tumors. (Pubmed Central) - Aug 25, 2022
P1
Sitravatinib demonstrated manageable safety and modest clinical activity in solid tumors. NCT02219711 (first posted August 14, 2014).
- ||| sitravatinib (MGCD516) / BeiGene
Enrollment status, Combination therapy, Metastases: Study of Sitravatinib With or Without Other Anticancer Therapies Receiving Clinical Benefit From Parent Study (clinicaltrials.gov) - Aug 25, 2022
P2/3, N=200, Enrolling by invitation, Sponsor: Mirati Therapeutics Inc.
NCT02219711 (first posted August 14, 2014). Recruiting --> Enrolling by invitation
- | Tevimbra (tislelizumab-jsgr) / BeiGene, sitravatinib (MGCD516) / BeiGene
Enrollment change, Trial completion date, Metastases: BGB-900-2001-IIT: A Phase II Study to Explore the Safety, Tolerability, and Preliminary Antitumor Activity of Sitravatinib Plus Tislelizumab or Combination With Nab-paclitaxel in Patients With Locally Recurrent or Metastatic Triple Negative Breast Cancer (TNBC) (clinicaltrials.gov) - Aug 3, 2022
P2, N=96, Recruiting, Sponsor: Fudan University
Recruiting --> Enrolling by invitation N=61 --> 96 | Trial completion date: Jan 2023 --> Jun 2023
- Baize'an (tislelizumab) / BeiGene, Novartis, sitravatinib (MGCD516) / Mirati
STELLAR: A Phase II, Open-Label, Single-Arm, Prospective Clinical Study of Tislelizumab Combined with Sitravatinib as Consolidation Treatment after Chemoradiotherapy in Locally Advanced, Unresectable Non-Small-Cell Lung Cancer (Henry B. Gonzalez Convention Center, Exhibit Hall 1) - Aug 1, 2022 - Abstract #ASTRO2022ASTRO_404;
P2
Screens: 26/3Purpose/Objective(s): Consolidation durvalumab has become the standard of care in patients with unresectable, stage III non-small-cell lung cancer (NSCLC) without disease progression after concurrent chemoradiation therapy (cCRT) based on the PACIFIC study. N/A
- || Tevimbra (tislelizumab-jsgr) / BeiGene, sitravatinib (MGCD516) / BeiGene
Trial completion date, Trial primary completion date, Combination therapy, Monotherapy, Metastases: BGB-900-104: A Study to Investigate Sitravatinib as Monotherapy and in Combination With Tislelizumab in Participants With Unresectable Locally Advanced or Metastatic Hepatocellular Carcinoma or Gastric/Gastroesophageal Junction Cancer (clinicaltrials.gov) - Aug 1, 2022
P1/2, N=111, Active, not recruiting, Sponsor: BeiGene
N/A Trial completion date: Oct 2022 --> Jun 2023 | Trial primary completion date: Aug 2022 --> Mar 2023
- | Tevimbra (tislelizumab-jsgr) / BeiGene, sitravatinib (MGCD516) / BeiGene
Enrollment open: BGB-Sitra-2001-IIT: A Study to Evaluate Tislelizumab Combined With Sitravatinib as Adjuvant Therapy in Participants With HCC at High Risk of Recurrence After Curative Resection (clinicaltrials.gov) - Jul 29, 2022
P2, N=52, Recruiting, Sponsor: Anhui Provincial Hospital
Trial completion date: Oct 2022 --> Jun 2023 | Trial primary completion date: Aug 2022 --> Mar 2023 Not yet recruiting --> Recruiting
- Baize'an (tislelizumab) / BeiGene, Novartis, sitravatinib (MGCD516) / Mirati
Phase III study of tislelizumab (TIS) with sitravatinib versus chemotherapy (chemo) in patients with locally advanced/metastatic non-small cell lung cancer (NSCLC) previously treated with chemo and an anti-programmed cell death protein 1/ligand 1 (PD-[L]1) antibody (Poster Area, Hall 4) - Jul 28, 2022 - Abstract #ESMO2022ESMO_2497;
P1b, P3
Secondary endpoints include investigator-assessed (INV) PFS, IRC-assessed objective response rate (ORR), duration of response (DoR), disease control rate (DCR), quality of life, safety, and pharmacokinetics (PK) of sitravatinib. Exploratory endpoints include INV-assessed ORR, DoR, DCR, PK of the active metabolite of sitravatinib, predictive and prognostic value of PD-L1 expression, and biomarker analysis.
- |||| Tevimbra (tislelizumab) / BeiGene, sitravatinib (MGCD516) / BeiGene
New P2 trial, Combination therapy, Metastases: Study To Investigate the Efficacy and Safety of Sitravatinib in Combination With Tislelizumab in Participants With Esophageal Squamous Cell Carcinoma (clinicaltrials.gov) - Jul 18, 2022
P2, N=100, Not yet recruiting, Sponsor: BeiGene
- |||| sitravatinib (MGCD516) / Mirati, Opdivo (nivolumab) / Ono Pharma, BMS
Clinical, P1/2 data, Combination therapy: Dose finding for our phase I-II trial of sitravatinib in combination with nivolumab was based on efficacy, toxicity & PROs/QOL. Not sure if any other oncology trials had done this before? If yes, would love to know. Tweetorial here 👇 (Twitter) - Jul 14, 2022
- Baize'an (tislelizumab) / BeiGene, Novartis, sitravatinib (MGCD516) / Mirati
Safety and Efficacy of Sitravatinib + Tislelizumab in Patients with PD-L1+, Locally Advanced/Metastatic, Non-Squamous NSCLC (Exhibit Hall - Hall B) - Jun 24, 2022 - Abstract #IASLCWCLC2022IASLC_WCLC_1427;
P1b
Exploratory endpoints include INV-assessed ORR, DoR, DCR, PK of the active metabolite of sitravatinib, predictive and prognostic value of PD-L1 expression, and biomarker analysis. Sitravatinib plus tislelizumab showed a manageable safety and tolerability profile and demonstrated antitumor activity in patients with PD-L1+, locally advanced or metastatic non-squamous NSCLC who had not received prior systemic treatment in the metastatic setting.
- Baize'an (tislelizumab) / BeiGene, Novartis, sitravatinib (MGCD516) / Mirati
Safety and Efficacy of Sitravatinib + Tislelizumab in Patients with PD-L1+, Locally Advanced/Metastatic, Squamous NSCLC (Exhibit Hall - Hall B) - Jun 24, 2022 - Abstract #IASLCWCLC2022IASLC_WCLC_1357;
P1b
Sitravatinib plus tislelizumab showed a manageable safety and tolerability profile and demonstrated antitumor activity in patients with PD-L1+, locally advanced or metastatic non-squamous NSCLC who had not received prior systemic treatment in the metastatic setting. Sitravatinib plus tislelizumab demonstrated a manageable safety and tolerability profile as well as antitumor activity in patients with PD-L1+, locally advanced or metastatic squamous NSCLC who had not received prior systemic treatment in the metastatic setting.
- Tabrecta (capmatinib) / Incyte, Novartis, Tepmetko (tepotinib) / EMD Serono, foretinib (GSK1363089) / Exelixis
Proposal of Foretinib as Second-Line TKI after Capmatinib/Tepotinib Treatment Failure in NSCLC with MET Exon 14 Mutation (Exhibit Hall - Hall B) - Jun 24, 2022 - Abstract #IASLCWCLC2022IASLC_WCLC_1090;
We then performed further growth inhibitory assays using these four candidates plus other four MET-TKIs (type Ib; capmatinib and tepotinib, type II; cabozantinib and merestinib) in Ba/F3 cells carrying METex14 plus one of MET D1228A/E/G/H/N/V/Y or Y1230C/D/H/N/S secondary mutations... The type II MET-TKI foretinib may be an appropriate second-line MET-TKI for NSCLCs carrying METex14 after campatinib/tepotinib treatment failure by secondary mutations at D1228 or Y1230 residues.212
- | Tabrecta (capmatinib) / Incyte, Novartis, Tepmetko (tepotinib) / EMD Serono, foretinib (GSK1363089) / Exelixis
Journal: Foretinib can overcome common on-target resistance mutations after capmatinib/tepotinib treatment in NSCLCs with MET exon 14 skipping mutation. (Pubmed Central) - Jun 20, 2022
The type II MET-TKI foretinib may be an appropriate second-line MET-TKI for NSCLCs carrying METex14 after campatinib/tepotinib treatment failure by secondary mutations at D1228 or Y1230 residues.212 The type II MET-TKI foretinib may be an appropriate second-line treatment for NSCLCs carrying METex14 after campatinib/tepotinib treatment failure by secondary mutations at residue D1228 or Y1230.
- || sitravatinib (MGCD516) / BeiGene, Keytruda (pembrolizumab) / Merck (MSD)
New P2 trial, Mismatch repair: Pembrolizumab With Sitravatinib in Recurrent Endometrial Cancer and Other Solid Tumors With Deficient Mismatch Repair System (clinicaltrials.gov) - Jun 15, 2022
P2, N=30, Not yet recruiting, Sponsor: Haider Mahdi
- Baize'an (tislelizumab) / BeiGene, Novartis, sitravatinib (MGCD516) / Mirati
Safety and Efficacy of Sitravatinib + Tislelizumab in Patients with PD-L1+, Locally Advanced/Metastatic, Squamous NSCLC () - Jun 12, 2022 - Abstract #IASLCWCLC2022IASLC_WCLC_433;
P1b
The type II MET-TKI foretinib may be an appropriate second-line treatment for NSCLCs carrying METex14 after campatinib/tepotinib treatment failure by secondary mutations at residue D1228 or Y1230. Sitravatinib plus tislelizumab demonstrated a manageable safety and tolerability profile as well as antitumor activity in patients with PD-L1+, locally advanced or metastatic squamous NSCLC who had not received prior systemic treatment in the metastatic setting.
- | Tevimbra (tislelizumab-jsgr) / BeiGene, sitravatinib (MGCD516) / BeiGene
New P2 trial: BGB-Sitra-2001-IIT: A Study to Evaluate Tislelizumab Combined With Sitravatinib as Adjuvant Therapy in Participants With HCC at High Risk of Recurrence After Curative Resection (clinicaltrials.gov) - Jun 7, 2022
P2, N=52, Not yet recruiting, Sponsor: Anhui Provincial Hospital
- ||||| sitravatinib (MGCD516) / Mirati
Biomarker, Clinical: A promising agent in immune-pretreated NSCLC is sitravatinib. Overview provided by Dr. Ross Soo at #RomeLung22. Encouraging efficacy signals but biomarkers are really needed to help justify any added toxicity with this approach in earlier lines. (Twitter) - May 16, 2022
- | Tevimbra (tislelizumab-jsgr) / BeiGene, sitravatinib (MGCD516) / BeiGene
Enrollment open: BGB-900-2003-IIT: A Study to Investigate the Efficacy and Safety of Tislelizumab Combined With Sitravatinib as Maintenance Therapy for ES-SCLC (clinicaltrials.gov) - May 15, 2022
P2, N=59, Recruiting, Sponsor: Zhejiang Cancer Hospital
Sitravatinib plus tislelizumab demonstrated a manageable safety and tolerability profile as well as antitumor activity in patients with PD-L1+, locally advanced or metastatic squamous NSCLC who had not received prior systemic treatment in the metastatic setting. Not yet recruiting --> Recruiting
- ||||| sitravatinib (MGCD516) / BeiGene, Opdivo (nivolumab) / BMS
Enrollment closed, Combination therapy, Checkpoint inhibition, Metastases: SAPPHIRE: Phase 3 Study of Sitravatinib Plus Nivolumab vs Docetaxel in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer (clinicaltrials.gov) - May 6, 2022
P3, N=532, Active, not recruiting, Sponsor: Mirati Therapeutics Inc.
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- | sitravatinib (MGCD516) / BeiGene, Opdivo (nivolumab) / BMS
Enrollment open, Trial initiation date, Metastases: SNAPI: Sitravatinib and Nivolumab for the Treatment of Metastatic or Advanced Clear Cell Renal Cell Cancer (clinicaltrials.gov) - May 4, 2022
P2, N=88, Recruiting, Sponsor: M.D. Anderson Cancer Center
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting | Initiation date: Jul 2021 --> May 2022
- | Tevimbra (tislelizumab-jsgr) / BeiGene, sitravatinib (MGCD516) / BeiGene
Enrollment open, Metastases: BGB-900-2001-IIT: A Phase II Study to Explore the Safety, Tolerability, and Preliminary Antitumor Activity of Sitravatinib Plus Tislelizumab or Combination With Nab-paclitaxel in Patients With Locally Recurrent or Metastatic Triple Negative Breast Cancer (TNBC) (clinicaltrials.gov) - May 4, 2022
P2, N=61, Recruiting, Sponsor: Fudan University
Not yet recruiting --> Recruiting | Initiation date: Jul 2021 --> May 2022 Not yet recruiting --> Recruiting
- Baize'an (tislelizumab) / BeiGene, Novartis, sitravatinib (MGCD516) / Mirati
The safety, tolerability, and preliminary antitumor activity of sitravatinib plus tislelizumab in patients with locally recurrent or metastatic triple-negative breast cancer. (Available On Demand; 448) - Apr 28, 2022 - Abstract #ASCO2022ASCO_1157;
P2
Not yet recruiting --> Recruiting Sitravatinib combined with tislelizumab demonstrated clinically meaningful anti-tumor activity and had a manageable safety profile.
- || sitravatinib (MGCD516) / Mirati, Opdivo (nivolumab) / Ono Pharma, BMS
P1/2 data, Clinical Trial,Phase I, Clinical Trial,Phase II, Journal: A phase 1-2 trial of sitravatinib and nivolumab in clear cell renal cell carcinoma following progression on antiangiogenic therapy. (Pubmed Central) - Apr 27, 2022
In addition, correlative studies demonstrated reduction of immune-suppressive myeloid cells in the periphery and tumor microenvironment following sitravatinib treatment. This study provides a rationally designed combinatorial strategy to improve outcomes of anti-PD-1 therapy in advanced ccRCC.
- |||| sitravatinib (MGCD516) / Mirati, Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
Combination therapy: The other related hypothesis is that sitravatinib will distinctly synergize with immune checkpoint combinations. This is being investigated in the ongoing phase I trial of sitravatinib in combination with nivolumab + ipilimumab 👉 https://t.co/ubITq1PVIx (Twitter) - Apr 22, 2022
- ||||| sitravatinib (MGCD516) / Mirati, Opdivo (nivolumab) / Ono Pharma, BMS
Clinical: Thank you @VivekSubbiah! @OncHahn has now designed & opened as a fellow the successor trial, a multicenter IIT testing sitravatinib + nivolumab in clear cell #kidneycancer following progression on prior immunotherapy 👉 https://t.co/xIjc1v81TK. @neerajaiims @montypal @NazliDizman (Twitter) - Apr 22, 2022
- ||| sitravatinib (MGCD516) / Mirati, Opdivo (nivolumab) / Ono Pharma, BMS
How to design academic IIT & execute it from start to finish ? A phase 1-2 trial of sitravatinib and nivolumab in clear cell renal cell carcinoma following progression on antiangiogenic therapy @ScienceMagazine @PavlosMsaouel 👏🏼https://t.co/u51yrRTYyE (Twitter) - Apr 22, 2022
- ||| sitravatinib (MGCD516) / Mirati, Opdivo (nivolumab) / Ono Pharma, BMS
@PavlosMsaouel congratulations on your study of sitra/nivo post VEGF! How are you thinking about the combo in comparison to the other TKI/IO options? #kidneycancer https://t.co/1rxSmWZGK8 (Twitter) - Apr 22, 2022
- ||| sitravatinib (MGCD516) / Mirati, Opdivo (nivolumab) / Ono Pharma, BMS
Wonderful work, congratulations Pavlos and team! Careful correlative analyses with distinct immunomodulatory effect from sitravatinib-nivolumab combo. (Twitter) - Apr 20, 2022
- |||| sitravatinib (MGCD516) / Mirati
Clinical: 5/11 Sitravatinib 150mg was quickly deemed too toxic, whereas 60mg (-1 level) was never tested. The design oscillated between 80 & 120mg without finding a clear winner based on the DLT/efficacy trade-off. Accrual also started to suffer as #kidneycancer treatments rapidly evolved. (Twitter) - Apr 20, 2022
- |||| Trial completion, Trial primary completion date, Combination therapy, Metastases: MRTX-500: Phase 2 Study of Glesatinib, Sitravatinib or Mocetinostat in Combination With Nivolumab in Non-Small Cell Lung Cancer (clinicaltrials.gov) - Apr 19, 2022
P2, N=211, Completed, Sponsor: Mirati Therapeutics Inc.
This study provides a rationally designed combinatorial strategy to improve outcomes of anti-PD-1 therapy in advanced ccRCC. Active, not recruiting --> Completed | Trial primary completion date: May 2021 --> Nov 2021
- | sitravatinib (MGCD516) / BeiGene
Trial completion date, Trial primary completion date, Metastases: AAAQ8661: Sitravatinib in Advanced Liposarcoma and Other Soft Tissue Sarcomas (clinicaltrials.gov) - Apr 6, 2022
P2, N=29, Active, not recruiting, Sponsor: Matthew Ingham
Active, not recruiting --> Completed | Trial primary completion date: May 2021 --> Nov 2021 Trial completion date: Jan 2022 --> Jan 2023 | Trial primary completion date: Dec 2021 --> Jan 2023
- | sitravatinib (MGCD516) / Mirati
Trial primary completion date: A Study to Evaluate the Effect of Mild, Moderate, and Severe Hepatic Impairment on Pharmacokinetics of Sitravatinib (clinicaltrials.gov) - Apr 6, 2022
P1, N=36, Recruiting, Sponsor: Mirati Therapeutics Inc.
Trial completion date: Jan 2022 --> Jan 2023 | Trial primary completion date: Dec 2021 --> Jan 2023 Trial primary completion date: Feb 2022 --> Jun 2022
- || sitravatinib (MGCD516) / BeiGene
Trial completion: A Study to Explore the Effect of Food Before a Single Dose of Sitravatinib (clinicaltrials.gov) - Apr 6, 2022
P1, N=36, Completed, Sponsor: Mirati Therapeutics Inc.
Trial primary completion date: Feb 2022 --> Jun 2022 Active, not recruiting --> Completed
- |||| Tevimbra (tislelizumab-jsgr) / BeiGene, Partruvix (pamiparib) / EMD Serono
Trial completion date, Trial primary completion date, Metastases: BGB-A317-290-LTE1: Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies (clinicaltrials.gov) - Mar 8, 2022
P3, N=300, Enrolling by invitation, Sponsor: BeiGene
Active, not recruiting --> Completed Trial completion date: Dec 2021 --> Dec 2022 | Trial primary completion date: Dec 2021 --> Dec 2022
- ||||| sitravatinib (MGCD516) / Mirati
Clinical, Checkpoint inhibition: Sitravatinib shows signals of enhancing checkpoint inhibitor efficacy in NSCLC progressing on immunotherapy https://t.co/k6OpSNGQO1 (Twitter) - Mar 8, 2022
- |||||| sitravatinib (MGCD516) / Mirati
Clinical, Checkpoint inhibition: #ESMOTAT22: In early-phase trials, sitravatinib has shown signals enhancing checkpoint inhibitor efficacy in #NSCLC progressing on immunotherapy, but confirmation of efficacy & tolerability adjustments are still needed. 👉https://t.co/jD8IqjSq5G @MartinReck2 (Twitter) - Mar 8, 2022
- ||| sitravatinib (MGCD516) / BeiGene, Keytruda (pembrolizumab) / Merck (MSD)
Enrollment open, Metastases: Sitravatinib Plus Pembrolizumab in Patients With Advanced Treatment-Na (clinicaltrials.gov) - Mar 7, 2022
P2, N=70, Recruiting, Sponsor: Sarah Goldberg
Trial completion date: Dec 2021 --> Dec 2022 | Trial primary completion date: Dec 2021 --> Dec 2022 Not yet recruiting --> Recruiting
- || sitravatinib (MGCD516) / BeiGene
New P1 trial: PK Study to Assess Drug-drug Interaction Between Sitravatinib and a P-gp Inducer and an Inhibitor. (clinicaltrials.gov) - Feb 23, 2022
P1, N=36, Recruiting, Sponsor: Mirati Therapeutics Inc.